James Garner, Kazia Therapeutics CEO
Little biotech developing Genentech castoff drug hits hurdle in glioblastoma platform trial
When the Global Coalition for Adaptive Research brought the PI3K inhibitor paxalisib into its platform trial for glioblastoma in early 2021, the drug’s developer …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.